Navigation Links
Watson Confirms Court Grants Preliminary Injunction Preventing Launch of Generic LOVENOX®
Date:10/28/2011

PARSIPPANY, N.J., Oct. 28, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States District Court for the District of Massachusetts has granted Momenta Pharmaceuticals, Inc. and Sandoz Inc.'s request for a preliminary injunction preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX®.  The Company said that it was reviewing the court's decision and would evaluate all available options, including an appeal.

Enoxaparin is a low molecular weight heparin indicated in the prophylaxis and treatment of deep vein thrombosis and prophylaxis of ischemic complications in unstable angina and non-Q-wave myocardial infarction. 

On September 19, 2011, Amphastar received U.S. Food and Drug Administration ("FDA") approval of its Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium Injection in the 30mg/mL, 40mg/mL, 60mg/mL, 80mg/mL,100mg/mL, 120mg/mL, 150mg/mL and 300mg/mL strengths.  Watson has the exclusive right to distribute Amphastar's Enoxaparin in the U.S. retail pharmacy channel.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

About Amphastar Pharmaceuticals, Inc.

Amphastar Pharmaceuticals, Inc., established in 1996, is a specialty and generic pharmaceutical company focusing on injectable, inhalation, and other categories of pharmaceutical products. Amphastar's state-of-the-art, aseptic, cGMP compliant facilities develop, manufacture, and market innovative proprietary and generic products using new technologies and delivery systems.

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing and outcome of the pending patent litigation and risks that an adverse outcome in such litigation could render Watson liable for substantial damages; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's quarterly report on form 10-Q for the quarter ended June 30, 2011 and Watson's annual report on Form 10-K for the year ended December 31, 2010. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

LOVENOX® is a registered trademark of Sanofi-aventis U.S. LLC.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)

CONTACTS:

Investors:
Patty Eisenhaur              
(862) 261-8141

Media:
Charlie Mayr
(862) 261-8030


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... -- RK Logistics Group, Inc. was awarded California ... Fremont, CA headquarters facility where it provides ... San Jose for hi-tech, pharmaceutical and biomedical ... with its Fremont Innovation District, is excited to strategically partner ... to the hundreds of biotech, pharma and biomed companies throughout ...
(Date:7/11/2017)... has awarded grants totaling more than $2 million to 16 ... Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers from ... Uniformed Services University of the Health Sciences in ... announced last night during a reception at the International Society ... Germany . ...
(Date:7/10/2017)... CLEVELAND , July 10, 2017  US medical ... billion in 2021, according to Medical Equipment ... released by Freedonia Focus Reports. Continued increases in demand ... the aging of the population and supported by gains ... associated equipment and supplies. New product introductions will also ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... ... LINET, an international leader in healthcare technology and a global supplier of hospital ... , Perfectly suitable for labor, delivery, recovery and postpartum; the revolutionary design of the ... of childbirth. The AVE 2 has many features that help make the birthing process ...
(Date:7/20/2017)... Waco, TX (PRWEB) , ... July 19, 2017 , ... ... announce the availability of temporomandibular joint (TMJ) treatment and dental implants in ... the TRIOS® intraoral scanner and the T-Scan™ by Tekscan®, they can capture details in ...
(Date:7/20/2017)... ... 19, 2017 , ... Adolfson & Peterson Construction (AP) continues ... As a leader in healthcare construction, AP has successfully built several well-known medical ... Midwest with Josh now on board. , Josh brings over nine years ...
(Date:7/20/2017)... ... ... a fun-filled, action-packed memoir of adventures. “Fidget” is the creation of published author, Carol ... summa cum laude graduate of Gardner Webb University. She has won numerous awards during ... public school, Lynn continued to pursue her love for music through playing piano, harp, ...
(Date:7/18/2017)... , ... July 18, 2017 , ... ... compliance and commercialization, has just announced two more sessions of its “From the ... into risk management activities. Led by David Cronin, Cognition’s CEO, the half-hour public ...
Breaking Medicine News(10 mins):